🎉 M&A multiples are live!
Check it out!

Neuren Pharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Neuren Pharma and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Neuren Pharma Overview

About Neuren Pharma

Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.


Founded

2004

HQ

Australia
Employees

11

Financials

LTM Revenue $124M

LTM EBITDA $88.7M

EV

$814M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Neuren Pharma Financials

Neuren Pharma has a last 12-month revenue of $124M and a last 12-month EBITDA of $88.7M.

In the most recent fiscal year, Neuren Pharma achieved revenue of $147M and an EBITDA of $126M.

Neuren Pharma expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Neuren Pharma valuation multiples based on analyst estimates

Neuren Pharma P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $9.2M $147M XXX XXX XXX
Gross Profit n/a $9.2M XXX XXX XXX
Gross Margin NaN% 6% XXX XXX XXX
EBITDA -$1.0M $126M XXX XXX XXX
EBITDA Margin -11% 86% XXX XXX XXX
Net Profit -$4.9M $0.1M XXX XXX XXX
Net Margin -54% 0% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Neuren Pharma Stock Performance

As of March 17, 2025, Neuren Pharma's stock price is AUD 12 (or $7).

Neuren Pharma has current market cap of AUD 1.5B (or $955M), and EV of AUD 1.3B (or $814M).

See Neuren Pharma trading valuation data

Neuren Pharma Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$814M $955M XXX XXX XXX XXX $0.56

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Neuren Pharma Valuation Multiples

As of March 17, 2025, Neuren Pharma has market cap of $955M and EV of $814M.

Neuren Pharma's trades at 6.6x LTM EV/Revenue multiple, and 9.2x LTM EBITDA.

Analysts estimate Neuren Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Neuren Pharma and 10K+ public comps

Neuren Pharma Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $814M XXX XXX XXX
EV/Revenue 5.6x XXX XXX XXX
EV/EBITDA 6.5x XXX XXX XXX
P/E 9.6x XXX XXX XXX
P/E/Growth -0.2x XXX XXX XXX
EV/FCF 7.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Neuren Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Neuren Pharma Valuation Multiples

Neuren Pharma's NTM/LTM revenue growth is -55%

Neuren Pharma's revenue per employee for the last fiscal year averaged $13.3M, while opex per employee averaged $1.9M for the same period.

Over next 12 months, Neuren Pharma's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Neuren Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Neuren Pharma and other 10K+ public comps

Neuren Pharma Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 1494% XXX XXX XXX XXX
EBITDA Margin 86% XXX XXX XXX XXX
EBITDA Growth -12583% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 31% XXX XXX XXX XXX
Revenue per Employee $13.3M XXX XXX XXX XXX
Opex per Employee $1.9M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 3% XXX XXX XXX XXX
R&D Expenses to Revenue 12% XXX XXX XXX XXX
Opex to Revenue 14% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Neuren Pharma Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Biopharmaceuticals comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Neuren Pharma M&A and Investment Activity

Neuren Pharma acquired  XXX companies to date.

Last acquisition by Neuren Pharma was  XXXXXXXX, XXXXX XXXXX XXXXXX . Neuren Pharma acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Neuren Pharma

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Neuren Pharma

When was Neuren Pharma founded? Neuren Pharma was founded in 2004.
Where is Neuren Pharma headquartered? Neuren Pharma is headquartered in Australia.
How many employees does Neuren Pharma have? As of today, Neuren Pharma has 11 employees.
Who is the CEO of Neuren Pharma? Neuren Pharma's CEO is Mr. Jonathan Pilcher.
Is Neuren Pharma publicy listed? Yes, Neuren Pharma is a public company listed on ASX.
What is the stock symbol of Neuren Pharma? Neuren Pharma trades under NEU ticker.
When did Neuren Pharma go public? Neuren Pharma went public in 2005.
Who are competitors of Neuren Pharma? Similar companies to Neuren Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Neuren Pharma? Neuren Pharma's current market cap is $955M
What is the current revenue of Neuren Pharma? Neuren Pharma's last 12-month revenue is $124M.
What is the current EBITDA of Neuren Pharma? Neuren Pharma's last 12-month EBITDA is $88.7M.
What is the current EV/Revenue multiple of Neuren Pharma? Current revenue multiple of Neuren Pharma is 6.6x.
What is the current EV/EBITDA multiple of Neuren Pharma? Current EBITDA multiple of Neuren Pharma is 9.2x.
What is the current revenue growth of Neuren Pharma? Neuren Pharma revenue growth between 2023 and 2024 was 1494%.
Is Neuren Pharma profitable? Yes, Neuren Pharma is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.